NCT07198659View on ClinicalTrials.gov

A Single-Arm Investigator-Initiated Tria (IIT) Evaluating the Safety and Preliminary Efficacy of Autologous Drug-Loaded Neutrophils (NeuMed) in Patients With Unresectable Pancreatic Cancer

EARLY_PHASE1RecruitingINTERVENTIONAL
Enrollment

3

Participants

Timeline

Start Date

July 14, 2025

Primary Completion Date

July 14, 2027

Study Completion Date

July 14, 2027

Conditions
Unresectable Pancreatic Cancer
Interventions
COMBINATION_PRODUCT

Monomethyl Auristatin E (MMAE) / autologous neutrophil biological agents

Isolate the patients' autologous neutriphil cells, induce and culture them with Monomethyl Auristatin E (MMAE) in a GMP-compliant laboratory. Prior to the reinfusion of neutrophil biological agents into patients, stereotactic radiotherapy with a dose of 2-6 Gy is administered to pancreatic cancer lesions. The number of neutrophils that were reinfused was 2.0-8.0x10\^8.

Trial Locations (1)

710000

RECRUITING

The First Affiliated Hospital of the PLA Air Force Military Medical University, Xi’an

All Listed Sponsors
lead

The First Affiliated Hospital of Air Force Medicial University

OTHER

NCT07198659 - A Single-Arm Investigator-Initiated Tria (IIT) Evaluating the Safety and Preliminary Efficacy of Autologous Drug-Loaded Neutrophils (NeuMed) in Patients With Unresectable Pancreatic Cancer | Biotech Hunter | Biotech Hunter